Evidence map›Paper›PMID 42629445›Full record

ArticleProstate cancer and prostatic diseases2026

Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report.

Stephanie Sun, Bilal Ashraf, Kallie White, Andrew J Armstrong

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephanie Sun *Duke University School of Medicine, Duke University, Durham, NC, USA.ORCID http://orcid.org/0009-0003-6865-844X
Bilal Ashraf *Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.ORCID http://orcid.org/0009-0008-2892-9184
Kallie WhiteDuke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
Andrew J ArmstrongDuke University School of Medicine, Duke University, Durham, NC, USA. andrew.armstrong@duke.edu.ORCID http://orcid.org/0000-0001-7012-1754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypersensitivity reactions (HSRs) are common complications of taxane chemotherapy and serve as a barrier to key therapies such as cabazitaxel for patients with metastatic androgen receptor modulation-resistant (mAPMR) prostate cancer.

methodsWe developed a multidisciplinary cabazitaxel rapid desensitization protocol and enacted it for two patients.

resultsBoth patients tolerated this protocol well and demonstrated at least a PSA50 response and delayed progression.

conclusionWe demonstrate that cabazitaxel desensitization is safe and clinically impactful in patients with severe hypersensitivity reactions to taxanes. Wider implementation of desensitization protocols may help ensure access to this critical therapy in mAPMR prostate cancer.

Identifiers

PMID42629445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.